KeyGene and Floragenex extend license agreement on Sequence Based Genotyping technology

admin publish 2015/8/19 14:17:14

Keygene N.V. and Floragenex Inc. announced recently that they have entered into an extended license agreement around KeyGene¡¯s Sequence Based Genotyping (SBG) technology. The agreement enables Floragenex to extend its SBG service offerings to include ddRAD-Seq in noncommercial and academic research across all species. The agreement further cements KeyGene¡¯s SBG technology licensing portfolio and advances Floragenex¡¯s position as a services leader in fractional genomic sequencing applications. Financial terms of the agreement were not disclosed.

¡°KeyGene is very pleased to strengthen its relationship with Floragenex through this extended SBG license agreement¡±, said Michiel van Eijk, CSO of KeyGene. ¡°Floragenex¡¯ expertise, professionalism and impressive track record with RAD-Seq across a wide range of genomes logically fit with a broader portfolio of SBG service offerings. This will accelerate the understanding of genetic variation in plants, animals and other organisms in a highly cost-efficient manner.¡±

¡°As one of the earliest companies to utilize next-gen DNA sequencing for genotyping studies, Floragenex is pleased to now offer clients additional capabilities around SBG and ddRAD-Seq¡±, said Rick Nipper, the President of Floragenex. ¡°Our genomics team looks forward to providing support for SBG projects and continuing our strong tradition of assisting the research and life sciences community¡±.

Prev£ºEvogene announces discovery and validation of novel plant targets for herbicides Next£ºIndonesia to subsidize 765,000 kl of biodiesel through end of 2015: report